胰腺癌肝转移患者多学科综合治疗临床分析-肿瘤防治研究.PDFVIP

154 2015 42 2 Cancer Res Prev Treat,2015,Vol.42,No.2 · · 肿瘤防治研究 年第 卷第 期 doi:10.3971/j.issn.1000-8578.2015.02.012 ·临床研究· 胰腺癌肝转移患者多学科综合治疗临床分析 李泽朝，周勇，罗诗樵 Clinical Analysis of Multimodality Treatments for Pancreatic Cancer Patients with Liver Metastases LI Zechao, ZHOU Yong, LUO Shiqiao Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China Corresponding Author: LUO Shiqiao, E-mail: luoshiqiao@ Abstract: Objective To analyze the clinical features of pancreatic cancer patients with liver metastasis and multimodality treatments, and to explore the impact of multimodality treatments on the prognosis of pancreatic cancer patients. Methods We retrospectively analyzed 64 pancreatic cancer patients with liver metastasis hospitalized in The First Affiliated Hospital of Chongqing Medical University from January 2009 to January 2012. Prognostic factors in clinical features and multimodality treatments were analyzed by Kaplan-Meier method and Cox regression model with SPSS19.0 software. Results The median survival time (MST) was 4 month. 6-month, 1-year and 2-year overall survival (OS) were 39.1%, 21.9% and 7.8% respectively. Univariate analysis revealed that there were significant differences in age, pain, anorexia, CA19-9, ALT and GGT levels, surgery, chemotherapy embolism/ transarterial chemotherapy, active treatment and multi-disciplinary treatment. Multivariate analysis showed that extrahepatic metastasis, pain, CA19-9, active treatment, surgery, chemotherapy embolism/transarterial chemotherapy and multi-disciplinary treatment were closely related to the survival and prognosis of patients. Conclusion In pancreatic cancer patients with liver metastases, pain, CA19-9 ≥1 000 u/ml and extrahepatic metastases at diagnosis are adverse progno